These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 11799582)

  • 21. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transferrin saturation versus reticulocyte hemoglobin content for iron deficiency in Japanese hemodialysis patients.
    Kaneko Y; Miyazaki S; Hirasawa Y; Gejyo F; Suzuki M
    Kidney Int; 2003 Mar; 63(3):1086-93. PubMed ID: 12631092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical practice guidelines for maintaining adequate iron status with intravenous iron dextran in hemodialysis patients.
    Peacock E; Lindenfeld SM
    ANNA J; 1999 Jun; 26(3):337-43. PubMed ID: 10633605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effectiveness of low-dose maintenance i.v. iron therapy: a dialysis facility's experience.
    Peter J; Finkelstein F
    Nephrol Nurs J; 2006; 33(1):71-4, 90. PubMed ID: 16538930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iron deficiency in patients with chronic kidney disease: potential role for intravenous iron therapy independent of erythropoietin.
    Post JB; Wilkes BM; Michelis MF
    Int Urol Nephrol; 2006; 38(3-4):719-23. PubMed ID: 17106764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of sodium ferric gluconate complex in iron-deficient pediatric hemodialysis patients.
    Kaskel FJ
    Nat Clin Pract Nephrol; 2006 May; 2(5):244-5. PubMed ID: 16932433
    [No Abstract]   [Full Text] [Related]  

  • 27. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF; Szczech L; Johnson C; Frankenfield D
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of iron sucrose for iron deficiency in patients with dialysis-associated anemia: North American clinical trial.
    Charytan C; Levin N; Al-Saloum M; Hafeez T; Gagnon S; Van Wyck DB
    Am J Kidney Dis; 2001 Feb; 37(2):300-7. PubMed ID: 11157370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron supplementation in end-stage renal disease patients.
    Matzke GR
    Am J Kidney Dis; 1999 Mar; 33(3):595-7. PubMed ID: 10070926
    [No Abstract]   [Full Text] [Related]  

  • 30. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
    Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
    Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintaining higher TSATs and other iron indices is beneficial in management of anemic hemodialysis patients.
    Besarab A; Dalton CL
    Nephrol Nurs J; 2001 Aug; 28(4):429-34. PubMed ID: 12143465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Should we limit the ferritin upper threshold to 500 ng/ml in CKD patients?
    Dukkipati R; Kalantar-Zadeh K
    Nephrol News Issues; 2007 Jan; 21(1):34-8. PubMed ID: 17269263
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anemia management: recognizing opportunities and improving outcomes through nursing interventions.
    Lewis M; Wick GS; Foret J
    Nephrol Nurs J; 2000 Oct; 27(5):507-12. PubMed ID: 16649326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Measuring the content of reticulocyte hemoglobin (CHr) in predialysis chronic renal failure (CRF) patients].
    Saito M; Tsuchiya K; Ando M; Akiba T; Nihei H
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):430-8. PubMed ID: 14509218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous iron therapy in chronic kidney disease and peritoneal dialysis patients.
    Folkert VW
    Nephrol Nurs J; 2003 Oct; 30(5):571-6, 584. PubMed ID: 14621635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of two iron gluconate treatment modalities in chronic hemodialysis patients: results of a randomized trial.
    Giordano A; Arrigo G; Lavarda F; Colasanti G; Petrini C
    J Nephrol; 2005; 18(2):181-7. PubMed ID: 15931646
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond.
    Mittman N
    Am J Kidney Dis; 1999 Jul; 34(1):173-6. PubMed ID: 10401035
    [No Abstract]   [Full Text] [Related]  

  • 39. The utility of zinc protoporphyrin for predicting the need for intravenous iron therapy in hemodialysis patients.
    Fishbane S; Lynn RI
    Am J Kidney Dis; 1995 Mar; 25(3):426-32. PubMed ID: 7872320
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Stability of hemoglobin levels: an indispensible paradigm change in medical management].
    Zaoui P; Deray G; Ortiz JP; Rostaing L
    Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H5-7. PubMed ID: 21371678
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.